Duavee Medicare Advantage Coverage: What Women Need to Know in 2026

What Is Duavee and Why Does Coverage Get Complicated?

Duavee is a fixed-dose combination of conjugated estrogens 0.45 mg and bazedoxifene 20 mg, approved by the FDA in October 2013 for moderate-to-severe vasomotor symptoms (hot flashes, night sweats) in postmenopausal women who have a uterus. Bazedoxifene acts as a selective estrogen receptor modulator (SERM) and replaces the progestogen component that would otherwise be needed to protect the uterine lining. That makes Duavee the only tissue selective estrogen complex (TSEC) on the U.S. Market.

Because it is a branded-only product with no generic equivalent as of early 2026, Duavee sits in an expensive tier on most formularies. Medicare Part D and Medicare Advantage drug plans each maintain their own formularies. A plan that covers one estrogen product may still exclude Duavee entirely, or place it on a tier that requires prior authorization, step therapy, or a high fixed copay.

How Medicare Advantage Handles Duavee Differently Than Original Medicare

Original Medicare (Parts A and B) does not cover outpatient prescription drugs. Coverage for drugs like Duavee falls under Part D, which can be delivered either as a standalone Prescription Drug Plan (PDP) or bundled inside a Medicare Advantage plan (also called Part C or MA-PD).

Each Medicare Advantage plan negotiates its own formulary with Pfizer and other manufacturers. That means:

• Plan A in your county may cover Duavee on Tier 3 with a $60 copay.
• Plan B in the same county may not list Duavee at all.
• Both are legal and compliant with Medicare rules.

This variability is not an error. It is by design. The Centers for Medicare & Medicaid Services (CMS) requires each Part D plan to cover at least two drugs in most therapeutic categories, but "menopause hormone therapy" is not a protected class under Part D, so plans have broad discretion to exclude individual agents.

The Step Therapy Problem

Many Medicare Advantage plans that do list Duavee on their formulary apply step therapy: you must try and document failure of a cheaper estrogen product (often oral conjugated estrogens 0.625 mg alone, or a transdermal estradiol) before the plan approves Duavee. For women who specifically cannot tolerate progestogens and need the TSEC mechanism, this can be medically inappropriate. Your clinician can submit a step therapy exception explaining why the required alternative is clinically unsuitable.

How to Check Whether Your Medicare Advantage Plan Covers Duavee

Do not guess. Call the member services number on the back of your insurance card and ask three specific questions:

1. Is NDC 00069-0151-30 (Duavee 30-tablet pack) on your current formulary?
2. What tier is it, and what is my copay or coinsurance at that tier?
3. Are there any restrictions: prior authorization, step therapy, or quantity limits?

You can also use the Medicare Plan Finder and enter Duavee by name to compare formulary status across every plan available in your ZIP code before open enrollment ends.

What "Not on Formulary" Actually Means for You

"Not on formulary" does not automatically mean you cannot get coverage. You have two formal pathways:

Formulary Exception Request. Your prescribing clinician submits a request arguing that Duavee is medically necessary and that no covered alternative is appropriate. If the plan denies it, you have the right to an independent review organization (IRO) appeal. IRO decisions are binding on the plan.

Coverage Determination Appeal. If your plan denies a prior authorization request, you escalate through a defined appeals ladder: redetermination by the plan, reconsideration by a Qualified Independent Contractor, ALJ hearing, Medicare Appeals Council, and federal court. The process takes time, but approval rates at higher appeal levels are meaningful for patients with documented clinical need.

What Duavee Actually Costs Without Coverage

The average retail cash price for a 30-day supply of Duavee runs approximately $240, though this varies by pharmacy and region. GoodRx and similar discount programs may reduce this somewhat at select pharmacies, but Duavee's branded status limits how low third-party discounts can push the price.

For context, the REPLENISH trial demonstrated that conjugated estrogens/bazedoxifene significantly reduced the frequency and severity of moderate-to-severe vasomotor symptoms versus placebo over 12 months, which is the core efficacy data Pfizer used for FDA approval. Women paying out of pocket are paying for that branded clinical package.

Pfizer's Patient Assistance and Savings Programs

Pfizer runs two relevant programs, though eligibility rules and availability change. Verify directly at Pfizer.com/assistance before counting on either.

Pfizer RxPathways. For commercially insured patients who meet income criteria, this program may reduce monthly out-of-pocket cost. Medicare beneficiaries are generally not eligible for manufacturer copay cards under federal anti-kickback rules, so this avenue is often closed to women on Medicare Advantage.

Pfizer Patient Assistance Program (PAP). Uninsured or underinsured patients below certain income thresholds may qualify for free or low-cost Duavee. Income limits and documentation requirements apply.

The federal restriction on manufacturer coupons for Medicare patients is worth understanding clearly: accepting a manufacturer coupon as a Medicare beneficiary can constitute an anti-kickback violation. This is why most coupon programs explicitly exclude Medicare, Medicaid, and TRICARE enrollees. If you see a Duavee coupon advertised without that exclusion, read the fine print.

Compounded Estrogen/SERM Combinations: A Realistic Alternative?

Compounded pharmacy alternatives to Duavee present a practical framework for understanding your options, but require careful clinical evaluation. Here is what is studied versus what is assumed:

What is directly studied: The FDA-approved Duavee formulation. The SMART trial program specifically evaluated this fixed-dose combination, confirming endometrial safety and vasomotor efficacy at the exact doses in the commercial product.

What is extrapolated: Compounded conjugated estrogens combined with a separately compounded SERM at similar doses. No large randomized controlled trial has evaluated a compounded TSEC for endometrial safety with the same rigor as the SMART trials. ACOG's 2022 menopause guidance and the Menopause Society (formerly NAMS) 2022 position statement both note that compounded hormones lack the quality-control data of FDA-approved products.

The honest clinical picture: For women on Medicare who are priced out of branded Duavee and cannot get coverage, a conversation with a knowledgeable menopause clinician about compounded options may be appropriate, with eyes open to the evidence gap. Cost savings can be substantial. The endometrial safety data at non-standard doses is not equivalent to the branded product.

Life-Stage Guide: Who Is Duavee Actually For?

Duavee is specifically indicated for postmenopausal women who still have a uterus. That framing matters clinically and for coverage decisions.

Postmenopausal Women (Primary Indication)

This is the FDA-approved population. If you are postmenopausal, have a uterus, experience moderate-to-severe vasomotor symptoms, and cannot tolerate or do not want to take a progestogen, Duavee is designed for you. The Menopause Society's 2022 hormone therapy position statement supports systemic estrogen therapy for vasomotor symptoms in appropriate candidates, and Duavee is one mechanism for delivering that therapy without separate progestogen.

Women who have had a hysterectomy do not need uterine protection and are better served by estrogen-alone products. Duavee adds cost and a drug component (bazedoxifene) that provides no additional benefit if there is no uterus to protect. Insurers sometimes flag this appropriateness issue during prior authorization review.

Perimenopausal Women

Duavee is not indicated for perimenopausal women. Perimenopause involves irregular but ongoing ovulation, and the endometrial protection mechanism of bazedoxifene has been studied in a postmenopausal, anovulatory context. Using Duavee during perimenopause carries theoretical endometrial risk from unopposed estrogen during ovulatory cycles. If you are perimenopausal and struggling with hot flashes, your clinician has other options, including low-dose oral contraceptives (which also provide contraception) and nonhormonal approaches.

Women Trying to Conceive

Duavee is not appropriate during the reproductive years for anyone attempting pregnancy. See the pregnancy section below.

Pregnancy, Lactation, and Contraception: Required Reading

Duavee is contraindicated in pregnancy. This is not a nuanced statement. Both conjugated estrogens and bazedoxifene carry known risks in pregnancy, and the FDA label carries a black box warning: exogenous estrogens should not be used during pregnancy.

Bazedoxifene is a SERM. SERMs as a class have shown embryotoxicity and fetal harm in animal studies. Human data on bazedoxifene exposure in pregnancy are absent because the drug is contraindicated, and no trials have enrolled pregnant women.

If you are premenopausal and prescribed Duavee off-label (which would be unusual and outside the approved indication), use reliable contraception. A pregnancy while taking Duavee should prompt immediate contact with your clinician.

Lactation: Duavee is contraindicated during breastfeeding. Exogenous estrogens suppress lactation and transfer into breast milk. Bazedoxifene lactation transfer data in humans are not available; animal data suggest transfer occurs. Women who are breastfeeding should not take Duavee.

Contraception note for perimenopausal women: Because Duavee is not an oral contraceptive and does not reliably suppress ovulation in a perimenopausal hormonal environment, it does not provide contraceptive protection. Perimenopausal women who could still conceive and who are on any hormone therapy should discuss contraception separately with their clinician.

Who Duavee Is Right For, and Who It Is Not

Right For

• Postmenopausal women with a uterus and moderate-to-severe hot flashes or night sweats
• Women who want systemic estrogen therapy but prefer to avoid a separate progestogen (due to side effects, personal preference, or risk concerns)
• Women whose clinicians have determined the estrogen/SERM mechanism is appropriate for their specific symptom and risk profile

Not Right For

• Women who have had a hysterectomy (no uterine protection needed; simpler estrogen-only products are appropriate)
• Perimenopausal women who are still ovulating
• Women who are pregnant or trying to become pregnant
• Women who are breastfeeding
• Women with a personal history of breast cancer, estrogen-dependent tumors, undiagnosed vaginal bleeding, or active thromboembolic disease (see full prescribing information for complete contraindications)
• Women on Medicare Advantage whose plan does not cover Duavee and who cannot afford the ~$240 cash price without assistance

How to Get Duavee Cheaper: A Practical Checklist

These strategies are listed roughly in order of effort and likelihood of success for a Medicare Advantage enrollee in 2026. Programs change frequently; verify every program before relying on it.

1. Use Medicare Plan Finder during open enrollment. Compare every plan in your ZIP code for Duavee formulary status. Switching plans is the single most reliable way to improve coverage.

2. Request a formulary exception. Have your clinician document why no covered alternative is clinically appropriate. Submit with the exception request.

3. Ask your clinician about step therapy exceptions. If your plan requires you to try a progestogen-containing regimen first, but you have a documented reason to avoid progestogens, a step therapy exception request may succeed.

4. Check Extra Help (Low Income Subsidy). If you qualify for Medicare's Extra Help program, your out-of-pocket cost for all Part D drugs drops significantly, sometimes to a few dollars per month even for high-tier drugs.

5. Ask about Pfizer PAP. If your income qualifies, the Pfizer Patient Assistance Program may supply Duavee at no cost. Medicare patients are excluded from the copay card program but may qualify for the PAP.

6. Discuss compounded alternatives with your clinician. A compounding pharmacy can prepare estrogen formulations at substantially lower cost. Your clinician should review the endometrial safety evidence gap before prescribing a compounded TSEC approach.

7. Consider switching to a covered estrogen-plus-progestogen regimen. If the reason you are on Duavee is convenience rather than progestogen intolerance, a covered combination product (such as Prempro or generic equivalents) may cost you far less.

8. Contact your State Health Insurance Assistance Program (SHIP). SHIP counselors are free, trained Medicare counselors who can review your specific plan options at no charge.

The Evidence Behind Duavee: What the Trials Show

The clinical data for Duavee comes primarily from the SMART (Selective estrogens, Menopause, And Response to Therapy) trial program, a series of randomized, placebo-controlled trials run by Pfizer. Key results:

• In SMART-1, endometrial hyperplasia rates at 12 months were below 1% in women taking conjugated estrogens 0.45 mg/bazedoxifene 20 mg, compared to 0% in placebo, meeting the FDA's non-inferiority threshold for endometrial safety.
• SMART-2 and SMART-3 confirmed statistically significant reductions in hot flash frequency and severity versus placebo. The SMART-2 results published in Menopause showed a mean reduction of approximately 74% in moderate-to-severe hot flash frequency at 12 weeks versus approximately 51% in placebo.
• SMART-5 evaluated breast density and mammographic findings, an important consideration for women with dense breast tissue or elevated breast cancer risk.

The trial population was postmenopausal women. There are no published randomized trial data on Duavee in perimenopausal women or in women with specific comorbidities such as PCOS or thyroid disease. Women were also predominantly white in the SMART trials, which is a limitation for generalizing results across racial and ethnic groups. This evidence gap is real and worth discussing with your clinician.

The Menopause Society notes that decisions about hormone therapy should be individualized, taking into account each woman's symptom burden, cardiovascular and breast cancer risk, bone health, and personal preferences, rather than applying population-level trial averages to individual decisions.

Bone Health: A Benefit That Sometimes Gets Overlooked

Bazedoxifene's SERM activity also confers a bone-protective effect. In the SMART-1 trial, women taking conjugated estrogens/bazedoxifene showed preservation of lumbar spine and total hip bone mineral density versus placebo at 24 months. For postmenopausal women who are both symptomatic and at elevated fracture risk, this dual benefit can be clinically meaningful and worth documenting in a prior authorization request, since it may support medical necessity arguments.

Osteoporosis affects approximately 10 million Americans, 80% of them women, and the perimenopausal and early postmenopausal years are when bone loss accelerates most rapidly. If your clinician has documented osteopenia or elevated fracture risk alongside vasomotor symptoms, that dual indication strengthens the medical necessity argument for coverage.

PCOS, Thyroid Disease, and Other Female Conditions: What We Know

PCOS: Duavee is not studied or indicated in women with PCOS. PCOS primarily affects reproductive-age women, and Duavee is contraindicated in premenopausal reproductive contexts. If a woman with a PCOS history reaches postmenopause with vasomotor symptoms, Duavee may be considered on the same basis as for any postmenopausal woman with a uterus; there is no specific contraindication, but there are no PCOS-specific trial data.

Thyroid disease: Oral estrogens, including conjugated estrogens, increase thyroid-binding globulin (TBG). Women on levothyroxine who start oral estrogen therapy often need a dose increase to maintain adequate free T4 levels. This is a pharmacokinetic interaction, not a contraindication, but it requires monitoring. If you take levothyroxine and start Duavee, your thyroid levels should be rechecked approximately 6 to 8 weeks after initiation.

Cardiovascular considerations: The Women's Health Initiative raised concerns about cardiovascular risks with combined estrogen-progestogen therapy, particularly when started in women more than 10 years past menopause. Duavee replaces the progestogen component with bazedoxifene, which has a different risk profile. However, coronary heart disease risk with Duavee has not been evaluated in a trial with cardiovascular outcomes as a primary endpoint. Women with established cardiovascular disease or multiple risk factors should discuss this specifically with their clinician.